A Phase I Study of PSB202 in People with Recurrent or Persistent Indolent B-Cell Lymphoma

Share

Full Title

A Phase 1a/1b Study of PSB202 in Patients with Previously Treated, Relapsed, Indolent B-Cell Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug PSB202 that can be given safely in people with indolent B-cell lymphoma that has come back or continued to grow despite treatment. PSB202 blocks the activity of proteins that contribute to cancer cell growth. By blocking these proteins, it may stop the growth of B-cell lymphomas. PSB202 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have indolent chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), or Waldenstrom’s macroglobulemia (WM) that has come back or continued to grow despite two prior regimens of treatment.
  • Patients’ cancers must make the CD20 protein (the targets of the drugs used in this study).
  • At least 4 weeks must pass between the completion of previous treatments and receipt of the study therapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Lindsey Roeker at 646-608-4115.

Protocol

22-131

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators